Disappointing weight-loss-drug trial results from Zealand Pharma send shares tumbling

Zealand Pharma's stock plunged following the announcement of disappointing Phase 1b trial results for its weight-loss drug, petrelintide. While the drug showed a significant placebo-adjusted weight loss of 8.6% at 16 weeks, investor expectations were likely higher given the competitive landscape dominated by more potent GLP-1 agonists like Novo Nordisk's Wegovy. This outcome casts doubt on petrelintide's market competitiveness and future development trajectory in the lucrative obesity drug market, signaling a potential shift in investor confidence and strategic focus for the company.